Galafold 123 MG
Ended Awarded
- Contract number
- 36C24525N0952
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $21,891
Award facts
- Contract value 100% obligated
- $21,891.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
Amicus Therapeutics US, LLC has been awarded a delivery order valued at $21,891.21 by Veterans Integrated Service Network 5 (VISN 5) for the supply of Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. This firm fixed-price delivery order, awarded on August 28, 2025, is a child contract under the parent Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule held by the Department of Veterans Affairs. The contract will be performed in Philadelphia, Pennsylvania, with an ultimate completion date of September 3, 2025. No set-aside designation was utilized for this award, and Amicus Therapeutics US, LLC serves as the prime contractor with no identified subcontractor involvement.
This delivery order supports the Veterans Health Administration's mission to provide specialized pharmaceutical products to veteran populations. VISN 5, which serves the Mid-Atlantic region, placed this task order under the larger VA FSS contract (36F79724D0185) valued at approximately $13 million and valid through August 31, 2029. The parent contract enables multiple Veterans Integrated Service Networks across the country, including VISNs 5, 7, 9, and 19, to procure Galafold for treating Fabry disease in VA healthcare facilities. These delivery orders typically support urgent pharmaceutical needs and demonstrate the VA's reliance on Amicus Therapeutics as a key supplier of this specialized rare disease treatment.
Quick answers
Who was awarded contract 36C24525N0952?
36C24525N0952 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 5 (Veterans Health Administration) on August 28, 2025.
How much is contract 36C24525N0952 worth?
The government has obligated $21,891 on 36C24525N0952.
Is contract 36C24525N0952 an order under another contract?
Yes. 36C24525N0952 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24525N0952 competed?
The extent of competition for 36C24525N0952 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award